Equities research analysts expect Cellectis SA (NASDAQ:CLLS) to post sales of $3.45 million for the current fiscal quarter, according to Zacks Investment Research. Four analysts have issued estimates for Cellectis’ earnings, with the lowest sales estimate coming in at $510,000.00 and the highest estimate coming in at $8.00 million. Cellectis reported sales of $8.34 million in the same quarter last year, which indicates a negative year over year growth rate of 58.6%. The business is scheduled to report its next earnings report on Wednesday, August 7th.
According to Zacks, analysts expect that Cellectis will report full-year sales of $14.78 million for the current financial year, with estimates ranging from $9.96 million to $27.40 million. For the next fiscal year, analysts anticipate that the firm will report sales of $48.31 million, with estimates ranging from $15.00 million to $82.04 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that cover Cellectis.
Cellectis (NASDAQ:CLLS) last announced its quarterly earnings data on Monday, March 11th. The biotechnology company reported ($0.53) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.14. Cellectis had a negative net margin of 401.24% and a negative return on equity of 14.85%. The company had revenue of $3.08 million during the quarter, compared to the consensus estimate of $7.46 million.
Shares of CLLS traded down $0.80 during midday trading on Tuesday, reaching $14.90. The stock had a trading volume of 7,090 shares, compared to its average volume of 104,142. The company has a market cap of $635.73 million, a PE ratio of -7.82 and a beta of 1.85. The company has a debt-to-equity ratio of 0.07, a current ratio of 9.77 and a quick ratio of 9.74. Cellectis has a one year low of $14.85 and a one year high of $31.30.
A number of institutional investors have recently modified their holdings of the business. Morgens Waterfall Vintiadis & Co. Inc. raised its stake in Cellectis by 94.1% in the 1st quarter. Morgens Waterfall Vintiadis & Co. Inc. now owns 33,000 shares of the biotechnology company’s stock worth $605,000 after purchasing an additional 16,000 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in Cellectis by 274.1% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,107 shares of the biotechnology company’s stock worth $130,000 after purchasing an additional 5,207 shares in the last quarter. Lazard Asset Management LLC increased its position in Cellectis by 24.4% during the 1st quarter. Lazard Asset Management LLC now owns 176,123 shares of the biotechnology company’s stock worth $3,230,000 after purchasing an additional 34,500 shares in the last quarter. ARK Investment Management LLC increased its position in Cellectis by 30.8% during the 1st quarter. ARK Investment Management LLC now owns 934,076 shares of the biotechnology company’s stock worth $17,131,000 after purchasing an additional 219,740 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its position in Cellectis by 42.2% during the 1st quarter. Envestnet Asset Management Inc. now owns 41,240 shares of the biotechnology company’s stock worth $756,000 after purchasing an additional 12,229 shares in the last quarter. Institutional investors and hedge funds own 30.63% of the company’s stock.
Cellectis Company Profile
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.
Read More: Why is Cost of Capital Important?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.